Malignant odontogenic tumors: epigenetics in disease and therapy

References

• Marin C, Dave M, Hunter KD. Malignant odontogenic tumours: a systematic review of cases reported in literature. Front Oral Health. 2021;2:775707.
   PubMedGoogle Scholar
• El-Naggar AK, Chan JKC, Grandis JR, et al. WHO classification of head and neck tumours. International Agency for Research on Cancer, World Health Organization (WHO); 2017.
   Google Scholar
• Mukherjee D, Das C, Chatterjee P. Odontogenic tumours of jaw: a prospective study on Clinico-Pathological profile and their management. Indian J Otolaryngol Head Neck Surg. 2017;69(2):181–186.
   PubMedGoogle Scholar
• Wright JM, Vered M. Update from the 4th edition of the world health organization classification of head and neck tumours: odontogenic and maxillofacial bone tumors. Head Neck Pathol. 2017;11(1):68–77.
   PubMed Web of Science ®Google Scholar
• D'Souza W, Saranath D. Clinical implications of epigenetic regulation in oral cancer. Oral Oncol. 2015;51(12):1061–1068.
   PubMed Web of Science ®Google Scholar
• Fagnocchi L, Mazzoleni S, Zippo A. Integration of signaling pathways with the epigenetic machinery in the maintenance of stem cells. Stem Cells Int. 2016;2016:8652748.
   PubMed Web of Science ®Google Scholar
• Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015;5(4):a006098–a006098.
   PubMed Web of Science ®Google Scholar
• Diniz MG, Gomes CC, de Sousa SF, et al. Oncogenic signalling pathways in benign odontogenic cysts and tumours. Oral Oncol. 2017;72:165–173.
   PubMed Web of Science ®Google Scholar
• Amm HM, MacDougall M. Molecular signaling in benign odontogenic neoplasia pathogenesis. Curr Oral Health Rep. 2016;3(2):82–92.
   PubMedGoogle Scholar
• Janisiak J, Kopytko P, Tkacz M, et al. Protein arginine methyltransferase (PRMT) inhibitors—AMI-1 and SAH are effective in attenuating rhabdomyosarcoma growth and proliferation in cell cultures. IJMS. 2021;22(15):8023.
   Google Scholar
• Salehinejad J, Zare-Mahmoodabadi R, Saghafi S, et al. Immunohistochemical detection of p53 and PCNA in ameloblastoma and adenomatoid odontogenic tumor. J Oral Sci. 2011;53(2):213–217.
   PubMedGoogle Scholar
• Yukimori A, Oikawa Y, Morita K, et al. Genetic basis of calcifying cystic odontogenic tumors. PLOS One. 2017;12(6):e0180224.
   PubMed Web of Science ®Google Scholar
• Coura BP, Bernardes VF, de Sousa SF, et al. KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features. Mod Pathol. 2019;32(6):799–806.
   PubMed Web of Science ®Google Scholar
• Bologna-Molina R, Ogawa I, Mosqueda-Taylor A, et al. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors. Oral Dis. 2019;25(2):481–487.
   PubMed Web of Science ®Google Scholar
• Aloka D, Padmakumar SK, Sathyan S, et al. Association of matrix metalloproteinase 2 and matrix metalloproteinase 9 gene polymorphism in aggressive and nonaggressive odontogenic lesions: a pilot study. J Oral Maxillofac Pathol. 2019;23(1):158.
   PubMedGoogle Scholar
• Guo Y, Xu C, Wu X, et al. Leptin regulates OPG and RANKL expression in gingival fibroblasts and tissues of chronic periodontitis patients. Int J Med Sci. 2021;18(11):2431–2437.
   PubMed Web of Science ®Google Scholar
• Sobocki BK, Basset CA, Bruhn-Olszewska B, et al. Molecular mechanisms leading from periodontal disease to cancer. IJMS. 2022;23(2):970.
   Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.
   PubMed Web of Science ®Google Scholar
• Sun Y, Niu X, Wang G, et al. A novel lncRNA ENST00000512916 facilitates cell proliferation, migration and cell cycle progression in ameloblastoma. Onco Targets Ther. 2020;13:1519–1531.
   PubMed Web of Science ®Google Scholar
• Moreira PR, Guimarães MM, Guimarães ALS, et al. Methylation of P16, P21, P27, RB1 and P53 genes in odontogenic keratocysts. J Oral Pathol Med. 2009;38(1):99–103.
   PubMed Web of Science ®Google Scholar
• Khojasteh A, Khodayari A, Rahimi F, et al. Hypermethylation of p16 tumor-suppressor gene in ameloblastic carcinoma, ameloblastoma, and dental follicles. J Oral Maxillofac Surg. 2013;71(1):62–65.
   PubMed Web of Science ®Google Scholar
• Moreira PR, Cardoso FP, Brito JAR, et al. Hypomethylation of tumor suppressor genes in odontogenic myxoma. Braz Dent J. 2011;22(5):422–427.
   PubMedGoogle Scholar
• Santos E-S, Rodrigues-Fernandes C-I, Cabral J-C, et al. Epigenetic alterations in ameloblastomas: a literature review. J Clin Exp Dent. 2021;13(3):e295–302–e302.
   Google Scholar
• Amaral-Silva G d, Morais TdL, Wagner VP, et al. Expression of DNMTs and H3K9ac in ameloblastoma and ameloblastic carcinoma. Front Oral Health. 2021;2:751162.
   PubMedGoogle Scholar
• Lu Y, Chan Y-T, Tan H-Y, et al. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19(1):79.
   PubMed Web of Science ®Google Scholar
• Liang Z, Wen C, Jiang H, et al. Protein arginine methyltransferase 5 functions via interacting proteins. Front Cell Dev Biol. 2021;9:725301.
   PubMed Web of Science ®Google Scholar
• Baldwin RM, Morettin A, Côté J. Role of PRMTs in cancer: could minor isoforms be leaving a mark? World J Biol Chem. 2014;5(2):115–129.
   PubMedGoogle Scholar
• Price OM, Thakur A, Ortolano A, et al. Naturally occurring cancer-associated mutations disrupt oligomerization and activity of protein arginine methyltransferase 1 (PRMT1). J Biol Chem. 2021 1;297(5):101336.
   PubMed Web of Science ®Google Scholar
• Hwang JW, Cho Y, Bae G-U, et al. Protein arginine methyltransferases: promising targets for cancer therapy. Exp Mol Med. 2021;53(5):788–808.
   PubMed Web of Science ®Google Scholar
• Yin X-K, Wang Y-L, Wang F, et al. PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer. Oncogene. 2021;40(7):1375–1389.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang D, Chen X, et al. PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. Cell Death Dis. 2021;12(11):1080.
   PubMed Web of Science ®Google Scholar
• Zhu Y, He X, Lin Y-C, et al. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. Blood. 2019;134(15):1257–1268.
   PubMed Web of Science ®Google Scholar
• Tang S, Sethunath V, Metaferia NY, et al. A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Rep. 2022;38(8):110417.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu M, Toyokawa G, Hayami S, et al. Dysregulation of PRMT1 and PRMT6, type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 2011 1;128(3):562–573.
   PubMed Web of Science ®Google Scholar
• Han M, Jia L, Lv W, et al. Epigenetic enzyme mutations: role in tumorigenesis and molecular inhibitors. Front Oncol. 2019;9:194.
   PubMed Web of Science ®Google Scholar
• Gregorova J, Vychytilova-Faltejskova P, Sevcikova S. Epigenetic regulation of MicroRNA clusters and families during tumor development. Cancers. 2021;13(6):1333.
   PubMed Web of Science ®Google Scholar
• Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol. 2019;51:11–17.
   PubMed Web of Science ®Google Scholar
• Setién-Olarra A, Marichalar-Mendia X, Bediaga NG, et al. MicroRNAs expression profile in solid and unicystic ameloblastomas. PLOS One. 2017;12(10):e0186841.
   PubMed Web of Science ®Google Scholar
• Niu X, Huang B, Qiao X, et al. MicroRNA-1-3p suppresses malignant phenotypes of ameloblastoma through down-regulating lysosomal associated membrane protein 2-mediated autophagy. Front Med. 2021;8:670188.
   PubMed Web of Science ®Google Scholar
• Davanian H, Balasiddaiah A, Heymann R, et al. Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature. Oncotarget. 2017;8(3):4530–4542.
   PubMedGoogle Scholar
• Jones PA, Ohtani H, Chakravarthy A, et al. Epigenetic therapy in immune-oncology. Nat Rev Cancer. 2019;19(3):151–161.
   PubMed Web of Science ®Google Scholar
• Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383(7):650–663.
   PubMed Web of Science ®Google Scholar
• Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28(10):1069–1078.
   PubMed Web of Science ®Google Scholar
• Gambacorta V, Gnani D, Vago L, et al. Epigenetic therapies for acute myeloid leukemia and their immune-related effects. Front Cell Dev Biol. 2019;7:207.
   PubMed Web of Science ®Google Scholar
• Quagliano A, Gopalakrishnapillai A, Barwe SP. Understanding the mechanisms by which epigenetic modifiers avert therapy resistance in cancer. Front Oncol. 2020;10:992.
   PubMed Web of Science ®Google Scholar